Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-01-02 |
2023-09 |
-0.05 |
N/A |
N/A |
N/A |
2023-10-05 |
2023-06 |
-0.05 |
N/A |
N/A |
N/A |
2023-05-18 |
2023-03 |
-0.23 |
N/A |
N/A |
N/A |
2023-03-30 |
2022-12 |
-0.19 |
N/A |
N/A |
N/A |
2022-11-08 |
2022-09 |
-0.24 |
N/A |
N/A |
N/A |
2022-08-04 |
2022-06 |
-0.29 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-03-07 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-03-01 |
SVB Leerink |
Downgrade |
Outperform |
Market Perform |
2022-08-26 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-08-16 |
Cowen & Co. |
Downgrade |
Outperform |
Market Perform |
2022-08-16 |
Truist Securities |
Downgrade |
Buy |
Hold |
2022-08-15 |
BMO Capital |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2020-10-25 |
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2020-01-09 |
ENRIGHT PATRICK G. |
Director |
0.00 |
Purchase |
2021-11-11 |
HOMBACH ROBERT J. CPA |
Director |
229.10K |
Purchase |
2021-12-01 |
KHANNA ASHISH |
Chief Financial Officer |
421.84K |
Purchase |
2021-05-16 |
KIDD ANDREW |
President |
101.04K |
Conversion of Exercise of derivative security |
2020-01-13 |
KOPPEL ADAM M |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-03-30 |
Bain Capital Life Sciences Investors, LLC |
8.89M |
641.98K |
13.13% |
2023-03-30 |
Adams Street Partners, LLC |
5.40M |
389.59K |
7.97% |
2023-03-30 |
Vanguard Group, Inc. (The) |
1.86M |
134.36K |
2.75% |
2023-03-30 |
Blackrock Inc. |
689.98K |
49.82K |
1.02% |
2023-03-30 |
Renaissance Technologies, LLC |
452.23K |
32.65K |
0.67% |
2023-03-30 |
Acadian Asset Management. LLC |
379.33K |
27.39K |
0.56% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Vanguard Total Stock Market Index Fund |
1.25M |
90.38K |
1.85% |
2022-12-30 |
Vanguard Extended Market Index Fund |
491.71K |
35.50K |
0.73% |
2023-02-27 |
Fidelity Extended Market Index Fund |
200.13K |
14.45K |
0.30% |
2023-02-27 |
iShares Micro Cap ETF |
104.86K |
7.57K |
0.15% |
2023-02-27 |
Fidelity NASDAQ Composite Index Fund |
71.54K |
5.17K |
0.11% |
2023-02-27 |
iShares Core S&P Total U.S. Stock Market ETF |
56.58K |
4.08K |
0.08% |